Novo Nordisk’s Pill Gamble: How Oral Wegovy Could Reshape the Obesity Market
Veröffentlicht: 27.06.2026 um 03:11 Uhr, Redaktion boerse-global.de
The obesity drug arena is undergoing a fundamental recalibration. Volume is exploding, but pricing power is eroding. At the centre of this tension sits Novo Nordisk, whose stock has clawed back some ground after a brutal slide—gaining roughly 8% over the past week to close at €42.12 on Friday. The recovery nudged the shares back above the 200-day moving average of €40.93, a technical milestone that offers some solace after a nearly 27% year-to-date decline.
Yet the rally has already pushed the relative strength index to 71.1, signalling overbought conditions. A short consolidation looks likely before the next leg, and the real test lies in whether the company can translate pipeline breakthroughs into sustainable margin expansion.
A First-Mover Advantage—on a New Front
The immediate catalyst is regulatory. Britain’s MHRA has approved the daily oral version of Wegovy for weight reduction, making the UK the first European market to clear the pill. This matters because the tablet is drawing in a largely untapped patient base: around 80% of users are new to GLP-1 therapy, and the oral formulation now accounts for roughly 60% of all new Wegovy prescriptions in the United States.
Britain’s National Institute for Health and Care Excellence has also endorsed the injectable version for cardiovascular risk prevention, widening the addressable population. The UK approval is widely viewed as a blueprint for other European regulators, potentially unlocking a huge cohort of patients who have been reluctant to use injections.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The Bull Case: Pipeline Depth and Production Ramp
Optimists point to a trio of pillars supporting the growth story. First, next-generation candidate CagriSema delivered a 22.7% average weight loss after 68 weeks in the REDEFINE-1 study. Although that trails Eli Lilly’s tirzepatide, which hit 25.5% in a comparable trial, the data are still strong enough to suggest a differentiated product. Second, another pipeline asset, Amycretin, showed a 14.6% weight reduction after 36 weeks in a Phase 2 trial, and a pivotal Phase 3 study is set to begin this year.
Third, manufacturing constraints are easing. A new production facility in Bohumil, Czech Republic, has started operations, aiming to resolve the supply bottlenecks that have plagued Wegovy in recent years. Flowing through to the top line, Novo Nordisk now commands roughly 55% of the global weekly injectable market, and Wegovy is available in over 55 countries.
The Bear Case: Price Caps, Patent Cliffs, and Rival Momentum
The headwinds are structural. In the United States, a recent agreement with the government has capped the monthly cost of GLP-1 therapies at $245, squeezing margins. Starting January 2027, Novo Nordisk will cut the list prices of Wegovy and Ozempic in the US. Meanwhile, patents on semaglutide are expiring in key markets. China, which contributes around 6.5% of group revenue, will see local generics flood in.
Competition is intensifying. Eli Lilly launched its rival product Foundayo in April 2026, and a major US pharmacy benefit manager has signalled a preference for Lilly’s drugs. Even CagriSema faces a perception gap: investors had set a 25% weight-loss benchmark for the class, and at 23% after 84 weeks, Novo’s candidate falls just short.
The financial outlook reflects this pressure. Management forecasts a 4% to 12% decline in currency-adjusted revenue and operating profit for 2026. The pre-tax profit drop is expected to be in the range of 5% to 13%, driven by the US pricing war.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Two Critical Catalysts Loom
The next fundamental checkpoint arrives with the second-quarter 2026 earnings. All eyes will be on patient adherence to the oral Wegovy tablet, particularly at higher doses. High retention is essential for recurring revenue.
The landmark event, however, is the FDA decision on CagriSema, expected in the fourth quarter of 2026. A clean approval without requests for additional data would be a powerful tailwind. Any delay or request for supplementary trials would likely trigger a setback, undermining the premium pricing that the pipeline is supposed to command.
With the oral Wegovy now landing in Europe and production capacity expanding, Novo Nordisk has a rare window to prove it can grow volumes fast enough to offset shrinking per-patient revenue. If it succeeds, the current recovery may have legs. If not, the stock’s bounce will look like a pause before further pain.
Ad
Novo Nordisk Stock: New Analysis - 27 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
